Background. Antitumor immunotherapy strategies, such as cytokinebased or cell-based immunotherapies, are designed to activate immune response against cancer cells, but considering that malignancy may be associated with the expansion of immunosuppressive components of antitumor immunity, it is likely that in such cases activation of the immune system would further enhance activity of these components, leading to more severe suppression of antitumor immune response thus making more favourable conditions for tumor progression.
Materials and methods. We studied the expression of biomarkers, representing immunosuppressive (FOXP3) and cytotoxic (perforin, IFN-γ) CD8 high CD57
+ T-cell subpopulation functions in the peripheral blood of 34 patients with advanced clear cell renal cell carcinoma (RCC) and 26 controls by multicolour flow cytometry.
Results. CD8 high CD57 + T cell subpopulation of all CD8 + T cells in RCC patients was significantly higher compared to age-matched healthy controls (p = 0.003). It was found that the mean percentage of suppressive CD8 high CD57 + FOXP3 + T-cell subset and cytotoxic CD8 high CD57 + Perforin + T-cell subset in the CD8 high CD57 + T-cell subpopulation was significantly increased in RCC patients compared to controls (p = 0.0004 and p = 0.008, respectively). There was no strong and biologically relevant negative correlation between the expression of FOXP3 and Perforin in the peripheral blood CD8 high CD57 + T-cell subpopulation of RCC patients.
Conclusions. Subsets of immunosuppressive FOXP3+ T cell and tumor-attacking (cytotoxic) Perforin+ T cells in the CD8
high CD57
+ T-cell subpopulation are significantly increased in RCC patients compared to controls. These quantitative rearrangements are independent and individual for each RCC patient.
INTRODUCTION
One of the functions of the immune system is to recognize and destroy tumor cells (1) , thus various approaches enabling to promote and enhance antitumor immune response have been introduced into clinical practice (2) . Antitumor immunotherapy strategies, such as cytokine-based or cell-based immunotherapies, are designed to activate immune response against cancer cells (3) , but considering that malignancy may be associated with the expansion of immunosuppressive components of antitumor immunity (4) , it is likely that in such cases activation of the immune system would further enhance activity of these components, leading to more severe suppression of antitumor immune response thus making more favourable conditions for tumor progression. Hence, it is likely that antitumor immunotherapy may be effective only when its prescription is based on immune system parameters, reflecting the nature of antitumor immune response (5) . Hardly ever it will be possible to assess all parameters of closely interacting mechanisms of antitumor immunity, so it is important to identify such immune system components, which would reflect the nature of antitumor immune response as accurately as possible.
One of the components might be CD8 high CD57 + T-cell subpopulation, which expansion is associated with chronic antigenic stimulation (6) (7) (8) , including tumor pathology (7, (9) (10) (11) . Our previous results showed that treatment with adjuvant IFN-α 2b significantly increased the survival of renal cell carcinoma (RCC) patients with higher levels (>30%) of CD8 high CD57 + T cells in CD8 + T-cell population, whereas no increase in the survival was observed in RCC patients with lower levels (<30%) of CD8 high CD57 + T cells, moreover, a tendency towards decreased survival was observed in the latter patient group (9). We also found that during treatment with IFN-α 2b lower pre-treatment values of CD8 high CD57
+ T cells tended to increase (IFN-α promotes their expansion and survival (12)), while higher pre-treatment values tended to decrease (9) (IFN-α may eliminate overactivated T cells (13) The aim of the current prospective pilot study was to evaluate the expression of biomarkers, representing immunosuppressive (FOXP3) and cytotoxic (perforin, IFN-γ) T-cell functions in the peri pheral blood CD8 high CD57
+ T-cell subpopulation of RCC patients and age-matched healthy controls. To our knowledge, the expression of FOXP3 in CD8 high CD57
+ T cells has not been investigated to date. Anyhow, currently FOXP3 is regarded as one of the main (but not absolute (23)) markers representing immunosuppressive properties of T cells (24, 25). Clear cell RCC is considered to be one of the most immunogenic malignancies in humans, however, non-individualized antitumor immunotherapy is effective only in about 10-30% of RCC patients (3, 26) , thus the need for its individualization is obvious.
MATERIALS AND METHODS

Patients and controls
Thirty-four patients with advanced clear cell renal cell carcinoma (RCC) and 26 healthy individuals were enrolled in the study during the period 2008-2010. All patients were treated at the Section of high CD57
+ T-cell subpopulation of patients with...
Oncourology, Second Department of Oncological Surgery, Institute of Oncology, Vilnius University. RCC was proven histologically in all cases. Pe ripheral blood samples were collected once from each participant: for RCC patients blood samples were taken on the 7th day after nephrectomy. All patients have never been treated with chemotherapy, radiotherapy or immunotherapy. Age-matched healthy control group subjects were enrolled in the study during their annual preventive medical examination. Control group included individuals without history of any oncological disease.
All participants (RCC patients and controls) were not affected with autoimmune diseases, acute or chronic infections (human cytomegalovi rus, hepatitis B virus, hepatitis C virus, human immu nodeficiency virus, M. tuberculosis), chro nic al coholism. Also they had no history of allo geneic bone marrow stem cell or solid organ transplantation.
The study was approved by the local Bioethical Committee and all individuals included in this study provided their informed written consent.
Flow cytometry 100 μl of ethylenediaminetetraacetic acid-collected blood samples were stained with the appropriate combination of three fluorochrome-labeled mono clonal antibodies (mAbs): anti-CD8-PerCP (pe ridinin-chlorophyll-protein) (BD Biosciences) and anti-CD57-FITC (fluorescein isothiocyanate) (BD Biosciences) combined with anti-FOXP3-PE (eBiosciences), anti-perforin-PE (BD Biosciences) or anti-IFNγ-PE (BD Biosciences).
For the detection of intracellular IFN-γ peripheral blood mononuclear cells (PBMCs) were separated from sodium citrate-collected peripheral blood by one-step density gradient centrifugation, using 8 ml (16 × 125 mm) BD Vacutainer® CPT TM tubes (BD Biosciences) according to the instructions of the manufacturer. Staining with ap propriate mAbs was performed after 6 hours of stimulation (1 × 10 6 cells per ml) with phorbol-12-myristate-13-acetate (5 ng/ml) (Fluka) and ionomycin (500 ng/ml) (Sigma Aldrich) in the presence of 10 μg/ml brefeldin A (Invitrogen) at 37 °C, 5% CO 2 atmosphere.
For surface antigen staining samples were incubated with 15 μl of the appropriate mAbs for 20 min at room temperature (RT) in the dark, then 1 ml of BD FACS TM Lysing Solution (BD Biosciences) was added to each sample (except stimulated PBMCs separated by density gradient centrifugation) and the samples were incubated for 10 min at RT in the dark.
For intracellular antigen staining, the cells were fixed and permeabilized with 1 ml of Fixation / Permeabilization solution (eBioscience) for 30 min at RT in the dark, washed twice with 2 ml of Permeabilization buffer (eBioscience) and incubated with 20 μl of anti-FOXP3-PE (eBioscience), anti-Perforin-PE (BD Biosciences) or anti-IFNγ-PE (BD Biosciences) mAbs for 30 min at RT in the dark. Cells were washed with 2 ml of Permeabilization buffer (eBioscience) and 1 ml of CellWash buffer (BD Biosciences), resuspended in 500 μl of CellWash buffer (BD Biosciences) and applied to flow cytometric analysis.
Each experiment included samples incubated with isotype controls -IgG 2a -FITC (Dako), IgG 1 -PE (phycoerythrin) (BD Biosciences) and IgG 2b -PE (BD Biosciences).
Assessment of intracellular IFN-γ expression after stimulation was also performed by comparing stimulated samples to non-stimulated controls.
Stimulation was not performed for the detection of intracellular perforin, since during initial experiments it was noticed that stimulation had no reliable impact on the expression level of perforin in either CD8 high CD57 + or CD8 high CD57 -T cells, however, increased non-specific staining with IgG 2b isotype control was observed after stimulation. Flow cytometric analysis was performed on a BD FACSort TM cytometer (BD Biosciences) with a single 488-nm argon ion laser and analyzed with the Cellquest software (BD Biosciences).
Statistical analysis
Distribution of the data was evaluated using the Shapiro-Wilk's W test. Differences between groups of parametrically-distributed data were evaluated using the Student's t test, while non-parametrically distributed data were evaluated using the Mann-Whitney's U test. Differences of the data within groups were evaluated using the Wilcoxon's criterion. Correlation between the expression of cytotoxic and immunosuppressive properties representing biomarkers was measured using the Spearman's rank correlation analysis. The p values <0.05 were considered significant. Differences of the data are presented as mean values ± standard deviation in the Results section. Statistical analyses were performed using the Statistica for Windows package version 8.0 (StatSoft Inc., Tulsa, OK, USA).
RESULTS
Quantitative changes within the peripheral blood CD8
+ T-cell population in advanced RCC pa tients We found that absolute counts of CD8 + T cells showed no significant differences between RCC patients and healthy controls, however, quantitative changes of various subpopulations were observed within the CD8 + T-cell population with the significant increase of CD8 high CD57
+ T-cell sub population in RCC patients compared to agematched healthy controls (Fig. 1 ). 
FOXP3
+ T-cell subset in healthy individuals represents the normal value range. to healthy controls (Fig. 2b) , whereas there were no significant differences in the expression of intracellular IFN-γ in CD8 high CD57
+ T cells (Fig. 2c) .
It should be noted that perforin, but not IFN-γ, was preferentially expressed in CD8 high CD57
+ T-cell subpopulation compared to CD8 high CD57
-T-cell subpopulation both in RCC patients and healthy controls (Fig. 2b-c) .
Both RCC patients and controls could be divided into different groups according to the level of cytotoxic CD8 high CD57 + Perforin + T-cell subset ( Table 2 ).
All subjects were grouped according to the percentage of perforin-expressing T lymphocytes in the CD8 + T-cell sub set was absent or low (Table 3) . 
DISCUSSION
CD8
high CD57 + T cells are absent at birth and gradually accumulate throughout lifetime as a result of persistent immune activation (21, 27, 28). Their expansion is associated with chronic intracellular infections (viral, some bacterial) (6, 7, 14, 29) , cancer (7, 9, 10, 17, 30-32), bone marrow or solid organ allogeneic transplantation (7, 16, 33) , some autoimmune diseases (6, 7, 33) , chronic alcoholism (33). The expansion of CD8 high CD57 + T-cell subpopulation also increases with ageing, however, this increase is not associated with age per se, but most likely is a result of persistent common viral infections, especially human cytomegalovi rus infection (7) .
Repeated stimulation with the same antigen gradually induces the loss of CD28 expression and gain of CD57 expression on memory CD8 + T cells (and to a substantially lesser extent on memory CD4 + T cells (7, 34, 35) ), eventually leading to the generation and accumulation of highly differentiated CD28 -/CD57 + T cells with eroded telomeres (6, 7, 34, 36) . These oligoclonally- + T-cell-mediated anti tumor immune response since the proportion of competing subsets may influence the overall effect of antitumor immunity and determine individual response to antitumor immunotherapy.
In our previous study we have found that treatment with adjuvant IFN-α 2b significantly increased the survival of RCC patients with higher levels (>30%) of CD8 high CD57 + T cells in the peripheral blood CD8 + T-cell population, whereas no increase in the survival was observed in RCC patients with lower levels (<30%) of CD8 high CD57 + T cells. Moreover, we observed a ten dency towards decreased survival in the latter RCC patient group (9). We have also showed that during treatment with IFN-α 2b lower pretreatment values of CD8 high CD57 + T cells tended to increase (IFN-α promotes their expansion and survival), while higher pre-treatment values tended to decrease in RCC or melanoma patients (9, 10) (IFN-α may eliminate overactivated T cells (13)). Collectively our data suggested that the expansion of immunosuppressive subsets in CD8 high CD57 + T-cell subpopulation might be prevailing in RCC patients. To check this hypothesis, in the current study we analyzed the CD8 high CD57
+ T-cell sub population and proportion of its various subsets in patients with advanced RCC and agemat ched healthy controls. It was found that although CD8 + T-cell concentration showed no sig nificant differences in the peripheral blood of RCC patients compared to healthy controls, quantitative rearrangements within the CD8 + T-cell subpopulation were observed with the significant increase of CD8 T-cell sub population, while in age-matched healthy controls we have not found any subject with so highly pronounced immunosuppressive component (Table 1 ). These data suggest that the increase of the immunosuppressive CD8 + T-cell subpopulation of advanced RCC patients compared to healthy controls, whereas CD8 high CD57 + IFNγ + T-cell subset showed no statistically relevant quantitati ve changes (Fig. 2b-c + T-cell subpopulation. Again, worth noting is the fact that an objective clinical response to antitumor immunotherapy is achieved in about 10-30% of RCC patients (3, 26), thus it is reasonable to presume that activation of the immune system (prescription of antitumor immunotherapy) might be the most effective, particularly for the patients with highly pronounced cytotoxic component in the absence of immunosuppressive chain, but this hypothesis should be confirmed in further clinical studies, one of which is being performed in our institution.
In conlusion, our data indicate that the immune system often attempts to combat cancer by mobilizing its cytotoxic effector components, but at the same time the competitive immunosuppressive chain which abolishes the cytotoxic antitumor immune response may increase as well. Exact mechanisms inducing expansion of the immunosuppressive component are not fully elucidated, although there is data that the increase of late-stage differentiated T cells with suppressor function may be tumorinduced (4) . The crucial point is that the amount of cytotoxic and immunosuppressive components of antitumor immunity is different in an individual cancer patient (at least with RCC) and the over all antitumor immune response may influence in dividual efficiency of antitumor immunotherapy. Eval uation of these differences may serve as one of possible immune system parameters enabling to assess the overall status of antitumor immune response and select cancer patients most suitable for antitumor immunotherapy while dismissing those to whom it would be ineffective or potentially harmful. 
CONCLUSIONS
CD8
Santrauka
Priešvėžinė imunoterapija, pavyzdžiui, citokinų arba ląstelių imunoterapija, yra skirta aktyvuoti imuninį atsaką, nukreiptą prieš vėžines ląsteles. Tačiau piktybinis navikas gali aktyvinti priešnavikinio imuniteto imu nosupresinius komponentus, todėl tikėtina, kad tokiais atvejais imuninės sistemos aktyvinimas gali dar labiau sustiprinti šių komponentų aktyvumą ir dar la biau slopinti priešnavikinį imuninį atsaką, sudarydamas palankesnes sąlygas navikui progresuoti.
Tyrimo medžiaga ir metodai. + T limfocitų subpopuliacijoje yra nepriklausomi ir individualūs kiekvie no išplitusia inkstų ląstelių karcinoma sergančio paciento.
Raktažodžiai: CD8 high CD57 + T limfocitai, cito toksiniai T limfocitai, imunosupresiniai T limfocitai, inkstų ląstelių karcinoma, individualizuota priešnavikinė imunoterapija
